Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bavarian Nordic A/S
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
June 26, 2024
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
June 17, 2024
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
May 31, 2024
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
April 29, 2024
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
April 02, 2024
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
February 23, 2024
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
August 06, 2023
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
August 03, 2023
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
June 27, 2023
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
June 20, 2023
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
February 15, 2023
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine
December 23, 2022
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults
December 22, 2022
From
Bavarian Nordic A/S
Via
GlobeNewswire
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial
October 17, 2022
From
Bavarian Nordic A/S
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.